Development of a stable radioiodinating reagent to label monoclonal antibodies for radiotherapy of cancer.
A method of radioiodinating monoclonal antibodies such that the labeled antibodies do not undergo in vivo deiodination has been studied. The method utilizes conjugation of succinimidyl para-iodobenzoate to the antibody. The iodobenzoate was radiolabeled by using an organometallic intermediate to facilitate the reaction. Thus, succinimidyl para-tri-n-butylstannylbenzoate was radiolabeled in 60-90% radiochemical yield and subsequently conjugated to the antibody in 80-90% yield. Animal biodistribution studies were carried out with two separate anti-melanoma antibodies (9.2.27 and NR-M1-05) labeled by this method, and examined in nude mice bearing human melanoma tumor xenografts. Very large differences in the localization of radioactivity were observed in the thyroids and stomachs of mice when the iodobenzoyl-labeled antibodies were compared with the same antibodies labeled using the chloramine-T method of radioiodination. Few other significant differences in the tissue distribution of the radioiodinated antibodies were seen.
Wilbur
D S
DS
NeoRx Corporation, Seattle, WA 98119.
Hadley
S W
SW
Hylarides
M D
MD
Abrams
P G
PG
Beaumier
P A
PA
Morgan
A C
AC
Reno
J M
JM
Fritzberg
A R
AR
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D004355:Drug Stability; D006801:Humans; D007202:Indicators and Reagents; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D007553:Isotope Labeling / Q000379:methods*; D008545:Melanoma / Q000532:radiotherapy; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000532:radiotherapy*; D014183:Transplantation, Heterologous
D000911:Antibodies, Monoclonal; D007202:Indicators and Reagents; D007457:Iodine Radioisotopes